Nuvo Pharmaceuticals Inc NRIFF

RE: Transcript: Coviden CEO on numbers... Pennsaid

[alpi1441]

Thanks for the link.

From the Q&A

Joanne Wuensch - BMO Capital Markets U.S.

And you launched several new products that were supposed to help outat the end of the year in Pharma such as EXALGO and PENNSAID. Could yougive us an update on uptake of these products please?

Richard Meelia

Sure, this is Rich. EXALGO's right on plan, doing very well and Ithink there's a lot of expectations that it may exceed our originalforecast, so that's good. PENNSAID, there's been some competitiveheadwinds as well as with some reimbursement issues. And so that wouldbe slightly behind where we thought it would be. But overall there, Imean, they're very profitable. And we still feel very positively aboutboth -- on the EXALGO is demonstrating the results, and we thinkPENNSAID, we understand what we need to do. So they're doing fine.